Literature DB >> 25160495

Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.

Grace Kam1, Richard Yiu, Yvonne Loh, Ai Leen Ang, Ling Ling Yueh, Yeow Tee Goh, Gee Chuan Wong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25160495     DOI： 10.1007/s00520-014-2417-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  20 in total

1.  Acute myeloid leukemia, version 2.2013.

Authors:  Margaret R O'Donnell; Martin S Tallman; Camille N Abboud; Jessica K Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael G Martin; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Eunice S Wang; Kristina M Gregory; Maoko Naganuma
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

2.  Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Authors:  Lorin K Roskos; Peggy Lum; Pamela Lockbaum; Gisela Schwab; Bing-Bing Yang
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

3.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

4.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Authors:  F A Holmes; J A O'Shaughnessy; S Vukelja; S E Jones; J Shogan; M Savin; J Glaspy; M Moore; L Meza; I Wiznitzer; T A Neumann; L R Hill; B C Liang
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.

Authors:  G Heil; D Hoelzer; M A Sanz; K Lechner; J A Liu Yin; G Papa; L Noens; J Szer; A Ganser; C O'Brien; J Matcham; A Barge
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.

Authors:  J L Harousseau; B Witz; B Lioure; M Hunault-Berger; B Desablens; M Delain; F Guilhot; P Y Le Prise; J F Abgrall; E Deconinck; D Guyotat; J P Vilque; P Casassus; O Tournilhac; B Audhuy; E Solary
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

8.  Management of fever in neutropenic patients with different risks of complications.

Authors:  Jean Klastersky
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Authors:  Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

10.  A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.

Authors:  Jorge Sierra; Jeffrey Szer; Jeannine Kassis; Richard Herrmann; Mario Lazzarino; Xavier Thomas; Stephen J Noga; Nigel Baker; Roger Dansey; Alberto Bosi
Journal:  BMC Cancer       Date:  2008-07-10       Impact factor: 4.430
View more
  2 in total

1.  A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia.

Authors:  Yan Qin; Xiaohong Han; Lin Wang; Ping Du; Jiarui Yao; Di Wu; Yuanyuan Song; Shuxiang Zhang; Le Tang; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2017-10       Impact factor: 5.087

Review 2.  Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Authors:  Matti Aapro; Ralph Boccia; Robert Leonard; Carlos Camps; Mario Campone; Sylvain Choquet; Marco Danova; John Glaspy; Iwona Hus; Hartmut Link; Thamer Sliwa; Hans Tesch; Vicente Valero
Journal:  Support Care Cancer       Date:  2017-08-25       Impact factor: 3.603
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.